In accord with ASX requirements, Imagion Biosystems’ quarterly financial statement Appendix 4C was lodged with the Australian Securities Exchange on 31 July, 2017, accompanied by commentary on the company’s recent IPO and management’s 12-18 month outlook.
View the Appendix 4C Announcement for Q2, 2017.
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December
December 2, 2025
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December Key Highlights: MagSense® HER2